Karamjit Gill

4.0k total citations · 2 hit papers
19 papers, 2.9k citations indexed

About

Karamjit Gill is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Karamjit Gill has authored 19 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 6 papers in Genetics. Recurrent topics in Karamjit Gill's work include Lymphoma Diagnosis and Treatment (16 papers), Viral-associated cancers and disorders (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Karamjit Gill is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Viral-associated cancers and disorders (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Karamjit Gill collaborates with scholars based in Canada, Portugal and United States. Karamjit Gill's co-authors include Joseph M. Connors, Randy D. Gascoyne, Richard Klasa, Laurie H. Sehn, Mukesh Chhanabhai, Judy Sutherland, C. P. Fitzgerald, Tamara Shenkier, Kerry J. Savage and Paul Hoskins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Seminars in Hematology.

In The Last Decade

Karamjit Gill

19 papers receiving 2.9k citations

Hit Papers

The revised International Prognostic Index (R-IPI) is a b... 2005 2026 2012 2019 2006 2005 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    2006 1.0k citations Laurie H. Sehn, Brian Berry et al. Blood profile →
  2. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
    2005 744 citations Laurie H. Sehn, Jane Donaldson et al. Journal of Clinical Oncology profile →

Peers

Karamjit Gill
Catherine Sebban France
Hervé Ghesquières France
Andreas Lohri Switzerland
Y Bastion France
Pierre Feugier France
Marita Ziepert Germany
Max Wolf Australia
Jonathon B. Cohen United States
Kay M. Ristow United States
Pauline Brice France
Catherine Sebban France
Karamjit Gill
Citations per year, relative to Karamjit Gill Karamjit Gill (= 1×) peers Catherine Sebban

Countries citing papers authored by Karamjit Gill

Since Specialization
Citations

This map shows the geographic impact of Karamjit Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karamjit Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karamjit Gill more than expected).

Fields of papers citing papers by Karamjit Gill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karamjit Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karamjit Gill. The network helps show where Karamjit Gill may publish in the future.

Co-authorship network of co-authors of Karamjit Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Karamjit Gill. A scholar is included among the top collaborators of Karamjit Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karamjit Gill. Karamjit Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gill, Sharlene, Shahid Ahmed, Scott Berry, et al.. (2023). Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022. Current Oncology. 30(9). 7964–7983. 1 indexed citations
2.
Sehn, Laurie H., Karamjit Gill, Abdulwahab J. Al-Tourah, et al.. (2014). Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood. 124(21). 392–392. 23 indexed citations
3.
Farinha, Pedro, Abdulwahab J. Al-Tourah, Karamjit Gill, et al.. (2009). The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 115(2). 289–295. 157 indexed citations
4.
Hui, David, Wwt Lam, Cynthia L. Toze, et al.. (2008). Alemtuzumab in clinical practice: A British Columbia experience. Leukemia & lymphoma. 49(2). 218–226. 9 indexed citations
5.
Al-Tourah, Abdulwahab J., Karamjit Gill, Mukesh Chhanabhai, et al.. (2008). Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(32). 5165–5169. 260 indexed citations
6.
7.
Wilson, Kenneth S., Laurie H. Sehn, Brian Berry, et al.. (2007). CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia & lymphoma. 48(6). 1102–1109. 46 indexed citations
8.
Al-Tourah, Abdulwahab J., Kerry J. Savage, Karamjit Gill, et al.. (2007). Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. Blood. 110(11). 790–790. 20 indexed citations
9.
Al-Tourah, Abdulwahab J., Karamjit Gill, Paul Hoskins, et al.. (2006). The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. Journal of Clinical Oncology. 24(18_suppl). 7510–7510. 12 indexed citations
10.
Sehn, Laurie H., Mukesh Chhanabhai, Karamjit Gill, et al.. (2006). Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. Blood. 108(11). 2739–2739. 1 indexed citations
11.
Sehn, Laurie H., Brian Berry, Mukesh Chhanabhai, et al.. (2006). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109(5). 1857–1861. 1033 indexed citations breakdown →
12.
Farinha, Pedro, Hamid Masoudi, Brian Skinnider, et al.. (2005). Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 106(6). 2169–2174. 376 indexed citations
13.
Sehn, Laurie H., Jane Donaldson, Mukesh Chhanabhai, et al.. (2005). Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology. 23(22). 5027–5033. 744 indexed citations breakdown →
14.
15.
Sehn, Laurie H., Jane Donaldson, C. P. Fitzgerald, et al.. (2004). Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.. Blood. 104(11). 1407–1407. 12 indexed citations
16.
Wilson, Kenneth S., Laurie H. Sehn, B. Berry, et al.. (2004). CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 22(14_suppl). 6526–6526. 6 indexed citations
17.
Wilson, Kenneth S., B. Berry, Mukesh Chhanabhai, et al.. (2004). CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 22(14_suppl). 6526–6526. 2 indexed citations
18.
Gill, Karamjit & John G. Kelton. (2000). Management of idiopathic thrombocytopenic purpura in pregnancy. Seminars in Hematology. 37(3). 275–289. 130 indexed citations
19.
Gill, Karamjit & John G. Kelton. (2000). Management of idiopathic thrombocytopenic purpura in pregnancy. Seminars in Hematology. 37(3). 275–289. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Sebban Breakdown of academic impact, for papers by Hervé Ghesquières Breakdown of academic impact, for papers by Andreas Lohri Breakdown of academic impact, for papers by Y Bastion Breakdown of academic impact, for papers by Pierre Feugier Breakdown of academic impact, for papers by Marita Ziepert Breakdown of academic impact, for papers by Max Wolf Breakdown of academic impact, for papers by Jonathon B. Cohen Breakdown of academic impact, for papers by Kay M. Ristow Breakdown of academic impact, for papers by Pauline Brice
Rankless by CCL
2026